Eyerising International has developed a myopia management device that uses Repeated Low-Level Red-Light therapy (RLRL).
Eyerising’s myopia management device uses patented technology to gently stimulate blood flow in the ocular fundus. The device is designed to alleviate scleral hypoxia and control axial lengthening.
One of the key advantages of this therapy is convenience – it takes just three minutes, twice a day, five days a week of therapy at home. Additionally, a simple touchscreen control makes it suitable for children as young as three years old.
The device has a good safety record and profile, is simple to use, non-invasive, and clinically proven to be effective with up to 87.7% efficacy in controlling myopia.
Visit: eyerisinginternational.com
